Efficacy, Safety and Immunogenicity of the Proposed Biosimilar Vedolizumab PB016 in Comparison With Entyvio®

NCT05771155 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

750

Enrollment

INDUSTRY

Sponsor class

Conditions

Ulcerative Colitis

Interventions

BIOLOGICAL: Intravenous (IV) infusions

Sponsor

Polpharma Biologics S.A.